Health care law company Frier Levitt has analyzed FDA enforcement steps from “research only” peptide suppliers. Their conclusion: the FDA considers a product’s classification dependant on its intended use, not its disclaimers. When Web sites involve dosage guides, reconstitution Recommendations, or hyperlink to message boards talking about hu